Perinatal hypoxia-ischemia or birth asphyxia is a serious complication with a high mortality
and morbidity. For decades, neuroprotective options have been explored to reduce …

Recent progress has provided us with several promising neuroprotective compounds to
reduce perinatal hypoxic-ischemic (HI) brain injury. In the early post HI phase, therapies can …

Objective This study was designed to investigate the indirect neuroprotective properties of
recombinant human erythropoietin (rhEPO) pretreatment in a rat model of transient middle …

The Regulator of G protein Signalling 4 (RGS4) is a multitask protein that interacts with and
negatively modulates opioid receptor signalling. Previously, we showed that the δ-opioid …

It is known that bone marrow-derived mesenchymal stem cells (BM-MSCs) are able to
improve neuronal function through secretion of trophic factors in animal models of middle …

Erythropoietin (Epo) plays a dual role as an erythropoiesis‐stimulating hormone and a
locally produced cytoprotectant in various vertebrate tissues. Splice variants and engineered …

Oxygen free radicals have been implicated in brain damage after neonatal asphyxia. In the
early phase of asphyxia/reoxygenation, changes in antioxidant enzyme activity play a pivotal …

Erythropoietin (EPO) has a neuroprotective effect in the animal model of ischemia/hypoxia,
but the mechanisms underlying the EPO effect in traumatic brain injury (TBI) are not well …

We live in a time of incredible scientific and medical break throughs, ranging from new
protective vaccines for respiratory syncytial virus and other diseases, to gene editing …

We aimed to evaluate diffusion tensor imaging (DTI) in infants born extremely preterm, to
determine the effect of erythropoietin (Epo) on DTI, and to correlate DTI with …